This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Analysts Estimate DuPont de Nemours (DD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DuPont de Nemours (DD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Olin (OLN) Q3 Earnings Beat Estimates
by Zacks Equity Research
Olin (OLN) delivered earnings and revenue surprises of 17.20% and 2.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
DuPont de Nemours (DD) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DuPont de Nemours (DD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pricing, Demand Up International Flavors (IFF) Despite Cost Woes
by Zacks Equity Research
Pricing actions, productivity initiatives, and investment in growth and acquisitions remain key drivers for International Flavors (IFF) despite inflationary cost pressures.
DuPont's (DD) Earnings and Revenues Trounce Estimates in Q2
by Zacks Equity Research
DuPont (DD) gains on strong demand in semiconductor, general industrial, water and construction end-markets and higher prices in Q2.
DuPont de Nemours (DD) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
DuPont de Nemours (DD) delivered earnings and revenue surprises of 18.92% and 2.07%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Eastman Chemical (EMN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Eastman Chemical (EMN) delivered earnings and revenue surprises of 5.20% and 1.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
DuPont (DD) Warms Up to Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DuPont (DD) is expected to have gained from strong end-market demand and its cost and pricing actions in Q2.
Tronox (TROX) Q2 Earnings Match Estimates
by Zacks Equity Research
Tronox (TROX) delivered earnings and revenue surprises of 0% and 4.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate DuPont de Nemours (DD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DuPont de Nemours (DD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DuPont de Nemours (DD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
DuPont de Nemours (DD) closed at $58.03 in the latest trading session, marking a +1.34% move from the prior day.
Do Options Traders Know Something About DuPont (DD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to DuPont (DD) stock based on the movements in the options market lately.
DuPont de Nemours (DD) Soars 5.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
DuPont de Nemours (DD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
DuPont de Nemours (DD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DuPont de Nemours (DD) closed at $55.35 in the latest trading session, marking a -1% move from the prior day.
Pricing Actions, Acquisitions to Aid International Flavors (IFF)
by Zacks Equity Research
Strong demand, pricing actions, productivity initiatives and investment in growth and acquisitions remain key growth drivers for International Flavors (IFF).
DuPont de Nemours (DD) Stock Moves -0.49%: What You Should Know
by Zacks Equity Research
DuPont de Nemours (DD) closed the most recent trading day at $67.64, moving -0.49% from the previous trading session.
DuPont de Nemours (DD) Down 2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DuPont de Nemours (DD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
International Flavors (IFF) Q1 Earnings Top Estimates, View Up
by Zacks Equity Research
International Flavors' (IFF) Q1 top line gains from solid growth in Health & Biosciences, Nourish and Pharma Solutions and additional sales related to the merger with N&B business.
DuPont's (DD) Earnings and Revenues Top Estimates in Q1
by Anindya Barman
DuPont (DD) gains on strong demand in electronics, industrial technologies, water and construction end-markets and higher prices in Q1.
DuPont de Nemours (DD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
DuPont de Nemours (DD) delivered earnings and revenue surprises of 22.39% and 0.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
DuPont (DD) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
DuPont (DD) is likely to have benefited from strong demand and productivity actions. However, higher raw material and logistics costs are expected to have hurt its Q1 results.
Earnings Preview: DuPont de Nemours (DD) Q1 Earnings Expected to Decline
by Zacks Equity Research
DuPont de Nemours (DD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DuPont de Nemours (DD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
DuPont de Nemours (DD) closed the most recent trading day at $67.80, moving +0.76% from the previous trading session.
DuPont de Nemours (DD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
DuPont de Nemours (DD) closed the most recent trading day at $68.84, moving -1.25% from the previous trading session.
International Flavors (IFF) Closes Health Wright Products Buyout
by Zacks Equity Research
International Flavors' (IFF) latest buyout provides formulation and finished format capabilities to Health & Biosciences probiotics, natural extracts and botanicals businesses.